Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial

Irene H. Langbakke*, Jakob N. Nielsen*, Mia P. Skettrup†, Angela Harper‡, Thomas Klitgaard§, Angelika Weil¶, Eva Engelhardt¶ and Martin Lange**

Departments of *Clinical Pharmacology, †Biostatistics, ‡Clinical Reporting, and §Biomodelling, Novo Nordisk A/S, Bagsvaerd, Denmark, ¶APEX Research, Munich, Germany, **Clinical Research, Novo Nordisk Inc, New Jersey, USA

Summary

Background GH may be beneficial in treating patients with end-stage renal disease (ESRD). However, the efficacy and safety of GH could be compromised by the potential for accumulation in the circulation.

Objective The objective was to investigate the pharmacokinetics and safety of GH treatment in ESRD patients.

Design This was an open, nonrandomized, single-centre parallel-group study lasting 8–9 days.

Subjects Eleven adult ESRD patients and 10 matched healthy individuals received recombinant human GH (50 μg/kg/day for 7 days) by subcutaneous injection; there were two dose reductions (25%) from Day 5/7. ESRD patients underwent dialysis four times.

Measurements Serum concentrations of GH, insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein-I (IGFBP-I), IGFBP-III and GHBP were measured. The primary endpoint was GH exposure [area-under-the-curve (AUC) calculated from the 24-h profile] on Days 7–8.

Results GH AUC\(_{0-24h}\) was greater for patients (387.91 ± 134.13 μg h/l) than healthy subjects (225.35 ± 59.63 μg h/l) and the 90% confidence interval (CI) for the estimated patient : healthy subject ratio (1.40–2.07) was not within the acceptance interval (0.67–1.50). GH AUC\(_{18-24h}\) for patients and healthy subjects (3.03 ± 2.71 μg h/l and 6.37 ± 4.21 μg h/l) returned approximately to baseline (2.86 ± 3.91 μg h/l and 1.09 ± 1.43 μg h/l); terminal half-life (\(t_{1/2}\)) was shorter for patients (2.28 ± 0.43 h vs. 3.23 ± 0.75 h). No major safety issues were identified.

Conclusions Results demonstrate a difference between patients and healthy subjects regarding GH AUC\(_{0-24}\). However, GH concentrations for both groups were comparable to baseline by 20–22 h, thus GH was not retained in the circulation of ESRD patients.

Introduction

Patients with end-stage renal disease undergoing haemodialysis commonly suffer from malnutrition, which represents one of the main clinical problems for these patients.\(^4\,5\) The prevalence of malnutrition in dialysis patients is reported to range from 30% to 50% or more.\(^2\,5\) The state of malnutrition and the malnutrition-induced systemic inflammation in patients with end-stage renal disease (ESRD) have been associated with the increased mortality and morbidity observed in these patients.\(^4\,5\) The cause of the poor nutritional status is multifactorial, and is associated with anorexia and reduced nutrient intake,\(^6\,10\,11\) metabolic and hormonal alterations,\(^12\) and catabolic effects associated with dialysis.\(^10\) Although as yet unproven, treatment of malnutrition in these patients can potentially improve clinical outcome and reduce the risk for morbidity and mortality. Thus, a number of preventive and therapeutic measures have been used to treat malnutrition in patients with ESRD, including anabolic hormones such as GH.

The potential beneficial effects of recombinant human GH (rhGH) in the treatment of patients with ESRD have been demonstrated both in short-term studies and long-term (up to 6 months) randomized, controlled trials. Treatment with rhGH has been shown to reduce protein catabolism,\(^13\,14\) increase muscle area and strength,\(^14\) increase erythropoietin synthesis,\(^19\) and to improve inflammation status and quality of life.\(^20\) A recent 6-month study showed a positive effect of GH treatment on lean body mass and cardiovascular risk factors.\(^21\) Furthermore, GH administration is associated with improvements in several nutritional parameters, such as increases in serum insulin-like growth factor-I (IGF-I),\(^13,14,22\) serum albumin\(^14\) and transferrin,\(^13\) and a reduction in blood urea nitrogen.\(^13\)

rhGH has become available for the treatment of children with chronic renal failure and has been shown to be safe and efficacious. However, the physiological response to exogenous GH treatment in adults may be different compared to that in children. As GH is
cleared partly by the kidneys in healthy subjects, investigation of a possible influence of renal impairment on drug elimination would be relevant. The primary aim of the current trial was thus to investigate the pharmacokinetic (PK) aspects and safety of treatment with rhGH (daily subcutaneous injection) in patients with ESRD compared with those in healthy subjects. A secondary objective was to investigate the pharmacodynamic (PD) responses to GH administration and to compare these in patients with ESRD and in healthy subjects.

Subjects and methods

Subjects

Twenty-two subjects (11 ESRD patients, 11 healthy subjects) were enrolled in the study and 21 subjects (mean age 51 years, range 24–66 years) received treatment with rhGH. There was one screening failure. One healthy subject withdrew consent prior to treatment and was withdrawn from the study. The study was performed at APEX Research Centre (Munich, Germany) in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice and was approved by local Ethics Committee. All subjects gave written informed consent. Subject demographics are presented in Table 1.

| Variable | Patients (N = 11) | Healthy subjects (N = 10) |
|----------|------------------|--------------------------|
| Age (years) | 51.3 ± 13.5 (24–66) | 50.2 ± 12.5 (28–64) |
| Sex, N (%) |                  |                          |
| Female | 3 (27)            | 3 (30)                   |
| Male | 8 (73)            | 7 (70)                   |
| Race, N (%) |              |                          |
| White | 11 (100)          | 10 (100)                 |
| Height (cm) | 176.5 ± 7.0 (163–189) | 172.5 ± 6.8 (162–182) |
| Weight (kg) | 77.5 ± 8.3 (62.2–92.1) | 78.3 ± 7.5 (63.5–90.8) |
| BMI (kg/m²) | 25.0 ± 3.2 (20.3–29.2) | 26.3 ± 1.8 (22.8–28.8) |
| Time in present HD treatment (years) | 2.1 ± 2.2* (0.3–6.7) | N/A |
| Kt/V | 1.4 ± 0.3 (1.2–2.1) | N/A |
| Systolic blood pressure | 127.7 ± 34.0 | 129.5 ± 10.3 |
| Diastolic blood pressure | 80.2 ± 9.3 | 81.3 ± 7.6 |
| Fasting plasma glucose (mmol/l) | 4.6 ± 0.5 | 4.8 ± 0.5 |

Values are the mean ± SD (range), except for sex and race, N (%). *Based on 10 patients. BMI, body mass index; HD, haemodialysis; N/A: not applicable.

Fig. 1 Trial design. All subjects had eight visits to the trial centre, seven daily doses of rhGH and a follow-up visit (Days 16–19). Patients had an additional assessment visit on Days 8–9, received an additional rhGH dose on Day 8 and had four dialysis sessions over the 9-day period.

This was an open, nonrandomized, parallel-group study, comprising eight visits for healthy subjects and nine visits for patients with ESRD. The following visits were included for all subjects (Fig. 1): screening visit, baseline visit (Days 0–1), outpatient visits (Days 2–6), assessment visit (Days 7–8) and a follow-up visit (Days 16–19).
Patients with ESRD received haemodialysis treatment on alternate days three times during the study, and had an additional assessment visit (Days 8–9), which included a dialysis session. The first dose of rhGH (Norditropin® SimpleXx®, Novo Nordisk A/S, Bagsvaerd, Denmark) was administered in the evening of Day 1 and daily dosing continued up to Day 7. Patients received an additional dose on Day 8 in order to record the GH exposure during dialysis. All subjects received a dose of 50 μg/kg body weight (bw)/day (maximum 4 mg/day) by subcutaneous injection. In case of unacceptable side effects the dose was to be lowered by 25% to 38 μg/kg/day for the rest of the study.

Measurements

The GH exposure of each subject was recorded at baseline and on Days 7–8 (also on Days 8–9 for patients only) by measuring GH concentration every 30 min (± 10 min) for 24 h, starting immediately after dosing at 20:00 h. GH exposure was determined as the AUC from the 24-h GH profile. The primary end-point was the GH exposure at steady-state (AUC\textsubscript{0–12 h}) on Days 7–8. Determination of GH in serum samples was performed using an enzyme-linked immunosorbsent assay (ELISA) method [kit 10–1900; Diagnostic Systems Laboratories (DSL) Inc, Webster, TX] with an intra- and interassay coefficient of variation (CV) of 4-0% and 6-5%, respectively. AUC\textsubscript{0–24 h} was calculated by the trapezoidal rule.

Secondary efficacy variables included PK and PD assessments. Fasting blood samples for analysis of PD variables in serum at screening and Day 8 were taken after an overnight fast. ELISA methods were used for all analyses (IGF-I: kit 10–5600, intra- and interassay CV 6-0% and 6-7%, respectively; IGFBP-I: kit 10–7800, intra- and interassay CV 2-9% and 6-9%, respectively; IGFBP-II: kit 10–6600, intra- and interassay CV 8-8% and 10-0%, respectively; GHBP: kit 10–48100, intra- and interassay CV 4-5% and 6-6%, respectively; kits all supplied by DSL Inc). The molar ratio for IGF-I/IGFBP-III was also calculated using the following equation:

\[
\frac{\text{IGF-I}(10^7-5)}{\text{IGFBP-III}(30-5)}
\]

The safety assessments included routine haematology and clinical chemistry, measured at baseline and on Day 8, and adverse events (AE), which were monitored daily during the study.

Statistical analysis

The primary analysis was based on a 90% CI of the ratio (patients: healthy subjects) of the AUC\textsubscript{0–24 h} of GH at steady-state (Days 7–8). With 10 subjects per group, a statistical power of more than 80% was obtained, enabling us to claim that the 90% CI lies embedded in the interval 67–150%. This interval was considered to be sufficiently narrow to allow us to evaluate whether or not renal disease had a clinically significant effect. The statistical power calculation was made based on the hypothesis that there was no difference between the mean AUC\textsubscript{0–24 h} in the two populations and a CV for AUC\textsubscript{0–24 h} of 30% (data on file, Novo Nordisk).\textsuperscript{26}

All subjects carried out trial procedures according to the protocol and were included in the primary analysis. For the primary analysis, a linear normal model (ancova) for the logarithmically transformed values of AUC\textsubscript{0–24 h} was used. The model included effects of subject group, daily dose/kg bw, and gender. From the model, the difference in means of the log-transformed values was estimated together with 90% CI and these estimates were then exponentially transformed in order to obtain estimates of the patients: healthy subjects ratio and 90% CI.

Secondary PK end-points AUC\textsubscript{0–12 h}, AUC\textsubscript{18–24 h}, AUC\textsubscript{0–12 h} and C\textsubscript{max} at steady-state were analysed as described for the primary end-point, as were total body clearance (Cl/f) and t\textsubscript{1/2,a} except that these end-points were considered to be dose-independent, thus the dose factor was omitted from the models. Time to reach maximum GH concentration (t\textsubscript{max}) was analysed using the nonparametric Kruskal–Wallis test based on Wilcoxon scores and the median difference between the two subgroups was estimated together with a 90% CI using the Hodges–Lehmann estimator.

Analysis of the PD end-points IGF-I and IGFBP-III was performed on the standard deviation score values, including an adjustment for gender. The following formula was used to calculate the SD score values:

\[
\text{SD score} = X - \frac{[(H + L)/2](H - L)}{4}
\]

where X corresponds to the biomarker and L and H are the respective low and high laboratory references (DSL Inc). Change from baseline to steady-state for all PD end-points was analysed between subject groups by an ancova, including subject group as fixed effect and the baseline assessment as covariate.

No statistical analyses were performed on the safety end-points.

The Statistical Analysis System software package (version 8.2; SAS Institute, Cary, NC) was used to analyse results. A P-value < 0.05 was taken to indicate significance and all statistical tests were two-sided.

Results

Trial subjects were recruited between June and November 2005. Of the 21 subjects allocated to treatment, a total of 20 (10 patients and 10 healthy subjects) completed the trial. One patient was withdrawn by the sponsor on Day 8 due to a shunt obstruction (evaluated as unlikely to be related to trial product by both investigator and sponsor), but was included in the primary outcome analysis on Days 7–8. There were two protocol deviations affecting six subjects: the follow-up visit for the withdrawn patient was performed later than planned and venous sampling for five subjects began later than 20:10 h (planned 20:00 h ± 10 min) for some visits. These were considered not to have had any bearing on the trial results.

At baseline, IGFBP-I and IGFBP-III values were significantly higher in patients compared with healthy subjects at baseline (Table 2), whereas GHBP values in healthy subjects at baseline were almost double those in patients (P = 0.01). There was no significant difference in IGF-I values or IGF-I/IGFBP-III molar ratio between patients and healthy subjects.

Primary end-point

The geometric mean GH AUC\textsubscript{0–24 h} at steady-state (Days 7–8) was two-thirds greater for patients than for healthy subjects (Table 3).
A difference between patients and healthy subjects was indicated by the fact that the 90% CI for the estimated patient : healthy subject ratio did not fall within the acceptance interval (0.67–1.50).

Secondary PK end-points

The GH AUC₀₋₂₄ h geometric mean at steady-state for patients was almost double that for healthy subjects (Table 3). Based on the 90% CI, a difference between patients and healthy subjects was indicated for this and all other secondary PK end-points. The geometric mean GH AUC₁₈₋₂₄ h for healthy subjects was double that for patients. Individual GH profiles on Days 7–8 are shown in Fig. 2. Of particular note is the fact that GH concentrations for both patients and healthy subjects were comparable with baseline values by about 20–22 h, demonstrating that administered rhGH does not seem to be retained in the circulation of patients with ESRD. Moreover, the geometric mean GH AUC₁₈₋₂₄ h steady-state for both patients and healthy subjects (Table 3) was about the same as the baseline mean values (Table 2). Individual GH profiles (not shown) for the period 18–24 h on Days 7–8 were relatively flat compared to the peaks obtained on Day 1 for all subjects (particularly noticeable for the patient group) (Fig. 2, inserts), demonstrating that administration of rhGH appeared to suppress endogenous GH production.

The geometric mean GH AUC₀₋₂₄ h steady-state for patients was two-thirds greater than that for healthy subjects. The Cₘₐₓ geometric mean for patients at steady-state was double that for healthy subjects. With regard to tₘₐₓ, the median values for patients and healthy subjects were approximately the same and no significant difference was found between patients and healthy subjects (P = 0.8). Individual GH profiles (Fig. 2) also demonstrated the higher GH concentration (Cₘₐₓ and AUC₀–₂₄ h) measured for patients compared to healthy subjects, and also that tₘₐₓ for both groups was reached in 4–5 h (range 3–9 h) after dosing.

The geometric mean of Cl/f at steady-state for healthy subjects was two-thirds greater than that for patients. Similarly, the geometric mean of t¹/₂,z for healthy subjects was greater (1.4 times) than that for patients.

In patients only, GH variables on Days 7–8 were compared with the same period on Days 8–9, which included a dialysis session (data not shown). There appeared to be no difference between values on Days 7–8 and Days 8–9 for any secondary PK end-point, except for AUC₁₈₋₂₄ h and tₘₐₓ (Days 7–8 mean values were greater than Days 8–9 values) and Cₘₐₓ (Days 8–9 values were greater).

### Table 2. Baseline endocrine parameters in the patients and healthy subjects

| Variable       | Patients (N = 11) | Healthy subjects (N = 10) | P-value (95% CI) |
|----------------|-------------------|---------------------------|-----------------|
| PTH (pmol/l)   | 39.9 ± 34.0 (4.0–109.1) | 3.8 ± 1.1 (2.4–6.1) | ND              |
| AUC₁₈₋₂₄₉h (µg h/l) | 2.86 ± 3.91 | 1.09 ± 1.43 | ND              |
| IGF-I SD score | −0.6 ± 0.9 (−1.7–0.9) | −1.0 ± 0.9 (−1.8–1.1) | 0.32 (−0.42; 1.24) |
| IGF-I (ng/ml)  | 210 ± 76 (117–322) | 178 ± 76 (111–362) | 0.30 (0.85; 1.66) |
| IGFBP-I (ng/ml) | 6.4 ± 42.3 (6.3–126.3) | 26.8 ± 28.3 (6.4–85.4) | 0.03 (1.08; 6.19) |
| IGFBP-III SD score | 2.2 ± 1.5 (−0.6–4.7) | 0.4 ± 0.8 (−1.3–1.5) | 0.004 (0.63; 2.90) |
| IGFBP-III (ng/ml) | 50.25 ± 1038 (3067–6654) | 37.08 ± 367 (3208–4211) | 0.002 (1.13; 1.57) |
| GHBP (pmol/l)  | 993 ± 610 (186–1972) | 1743 ± 512 (1134–2586) | 0.01 (0.27; 0.82) |
| IGF-I/IGFBP-III molar ratio | 0.2 ± 0 (0.1–0.2) | 0.2 ± 0.1 (0.1–0.4) | 0.37 (0.68; 1.16) |

Values are the mean ± SD (range), except for AUC₁₈₋₂₄₉h (mean ± SD).

PTH, parathyroid hormone; ND, not done; IGF-, insulin-like growth factor-; IGFBP-, insulin-like growth factor binding protein-; SD, standard deviation.

### Table 3. Primary and secondary pharmacokinetic (PK) efficacy endpoints at steady-state (Days 7–8)

| Variable              | Patients (N = 11) | Healthy subjects (N = 10) | Patients : healthy subjects ratio | 90% CI |
|-----------------------|-------------------|---------------------------|----------------------------------|-------|
| AUC₀₋₂₄ h (µg h/l)*   | 387.91 ± 134.13   | 225.35 ± 59.63            | 1.71                             | 1.40; 2.07 |
| AUC₀₋₁₂ h (µg h/l)    | 360.16 ± 134.04   | 194.00 ± 57.42            | 1.84                             | 1.49; 2.26 |
| AUC₁₈₋₂₄ h (µg h/l)   | 3.03 ± 2.71       | 6.37 ± 4.21               | 0.48                             | 0.26; 0.88 |
| AUCₑ₈₋₂₄ h (µg h/l)   | 388.90 ± 134.07   | 228.53 ± 60.45            | 1.69                             | 1.39; 2.05 |
| Cₘₐₓ (µg/l)           | 55.15 ± 26.87     | 27.29 ± 10.90             | 1.99                             | 1.53; 2.59 |
| tₘₐₓ (h)              | 5.00 (3.00; 6.50) | 4.50 (3.50; 9.00)         | N/A                              | −1.0; 1.0 |
| Cl/f (l/h)            | 9.64 ± 3.61       | 16.45 ± 6.11              | 0.59                             | 0.45; 0.76 |
| t¹/₂,z (h)†           | 2.28 ± 0.43       | 3.23 ± 0.75               | 0.71                             | 0.60; 0.83 |

Values are the geometric mean ± SD, except for tₘₐₓ [median (minimum; maximum)].

*Primary end-point; †Terminal half-life; N/A, not applicable.
Primary PD end-points

The mean PD data showing change from baseline to steady-state are presented in Table 4. Only IGFBP-III and associated SD score showed a significant difference ($P = 0.001$) between patients and healthy subjects. IGF-I SD score, and to a lesser extent IGFBP-III SD score, increased in both groups compared with baseline, whereas GHBP, and to a lesser extent IGFBP-I, decreased. The IGF-I/IGFBP-III molar ratio increased slightly for both groups, but there was no significant difference between groups. It should be noted that data for all biomarkers, except IGFBP-III, were highly variable, as depicted in the SDs, particularly in the patient group.

There was no significant difference in any of the PD biomarker values on Days 7–8 compared with Days 8–9 in ESRD patients (data not shown).

Secondary PD end-points

Safety

No major safety issues were identified during the trial. The most common adverse events were headaches (13 events, reported equally between patients and healthy subjects) and peripheral oedemas (six events, all but one in healthy subjects). During the trial, two subjects had the rhGH dose reduced. One patient experienced a severe adverse event (vomiting), which lasted a day and one healthy subject had a headache that lasted for 8 days. These events were considered probably related to trial product and the dose of rhGH was reduced on Day 7 and Day 5, respectively.

Discussion

In this study, treatment with GH did result in higher exposure in patients with ESRD than in healthy subjects on Days 7–8, as...
Table 4. Secondary pharmacodynamic (PD) efficacy end-points at steady-state (Days 7–8), change from baseline

| Variable, change from baseline | Patients (N = 11) | Healthy subjects (N = 10) | Patients – healthy subjects difference | P-value (95% CI) |
|--------------------------------|-------------------|----------------------------|----------------------------------------|----------------|
| IGF-I SD score                 | 9·3 ± 4·5         | 7·7 ± 1·5                  | 0·84                                   | 0·55 (–2·08; 3·76) |
| IGF-I (ng/ml)                  | 756 ± 361         | 630 ± 98                   | 74·4                                   | 0·51 (–1·59; 3·08) |
| IGFBP-I (ng/ml)                | −31·6 ± 39·6      | −18·7 ± 27·8               | 12·7                                   | 0·36 (–15·6; 41·0) |
| IGFBP-III SD score            | 3·4 ± 0·6         | 2·2 ± 0·5                  | 1·22                                   | 0·001 (0·58; 1·86) |
| IGFBP-III (ng/ml)             | 2615 ± 467        | 1693 ± 370                 | 1029                                   | 0·001 (505; 1533) |
| GHBP (pmol/l)                 | −74·1 ± 167·2     | −195 ± 134·9               | 69·6                                   | 0·40 (–100; 239)  |
| IGF-I/IGFBP-III molar ratio   | 0·3 ± 0·2         | 0·4 ± 0·0                  | −0·07                                  | 0·20 (–0·18; 0·04) |

Values are the mean ± SD. IGF-I, insulin-like growth factor-I; IGFBP-I, insulin-like growth factor binding protein-I; SD, standard deviation.

The wide variation in the GH half-lives reported in the literature has been explained by the use of different methodologies, and interference by the secretion of endogenous GH.23–25 A limitation of the current study therefore is that endogenous GH secretion was not suppressed. Nevertheless, our results were in agreement with other studies, and the fact that individual GH profiles at 18–24 h on Days 7–8 were relatively flat compared to those obtained on Day 1 suggests that GH administration did suppress endogenous GH production to some extent.

The reduced clearance observed for ESRD patients in the current study (58% of that for healthy individuals) is in agreement with other studies which have demonstrated a reduction in the metabolic clearance rate (MCR) of GH of about 50% for patients with chronic renal failure, and commensurate with a GH plasma half-life double that of healthy controls.23–25 GH appears to be eliminated in humans by a biocompartmental model,25,33 with unbound GH in a central compartment and GHBP and bound GH in a peripheral compartment. In healthy individuals, the kidney accounts for about 50% of the total MCR,25 and it is less than this in patients with renal disease,24 whereas extrarenal elimination (mostly via the liver) does not seem to differ significantly between the two groups.21 However, the situation is made more complex by the fact that GH also exists (reversibly) bound to GHBP, which is decreased in ESRD patients; the relative amounts of bound GH will most likely also correlate with the GH elimination rate.

No major safety concerns were raised with this trial. The high mean $C_{\text{max}}$ (double that for healthy controls) and greater $\text{AUC}_{0-24\text{h}}$ observed for patients with ESRD might be considered to have the potential to adversely influence the safety profile of rhGH. However, this seems not to be the case as GH appeared to be well tolerated generally and no differences in the safety profiles between the two groups were observed. The most common adverse events were headache and peripheral oedema, but these were not unexpected and neither occurred with greater incidence in the ESRD patient group. It is known that short-term rhGH administration can lead to fluid retention.34 In this trial, most events of oedema occurred in healthy subjects, probably because body fluid control is strictly regulated during dialysis treatment. One patient and one healthy subject had a GH dose reduction. The rhGH dose chosen was the highest dose employed in a previous trial of subcutaneous GH treatment in 139 patients with ESRD (37 dosed with 50 μg/kg bw/day, as in this trial), where GH treatment was found to be safe.21
With respect to standard GH biomarkers at steady-state, only IGFBP-III showed a significant difference between patients and healthy subjects after GH treatment and was greater for patients. Patients with ESRD are often resistant to GH and have a diminished rate of secretion of IGF-I. In concordance with previous trials, this study demonstrated an increase in IGF-I and IGF-I SD score in patients with ESRD after treatment with GH. There was a similar increase in healthy subjects, and no significant difference between the two groups was observed. Concerns have been raised regarding the potential risk of cancer associated with increased IGF-I as a result of GH exposure, and the molar ratio of IGF-I and IGFBP-III may be important in determining the relative risk of malignancy. The lower concentrations of IGFBP-III and IGFBP-III SD score were significantly greater for patients compared with healthy subjects, as has been observed previously during GH treatment of patients receiving haemodialysis, both IGF-I and the IGF-I/IGFBP-III molar ratio increased for both patients and healthy subjects, as was also reported previously, and there was no significant difference between groups. A possible role for IGF-I monitoring has been suggested to avoid morbidities associated with IGF-I excess, as well as deficiency. It should be noted that size-exclusion chromatography (to exclude any immunoreactive fragments of IGFBP-III formed as a result of IGFBP-III protease activity) was not performed in this study; therefore, concentrations of IGFBP-III may have been overestimated.

In agreement with previous reports, the baseline concentrations of IGFBP-III and IGFBP-III SD score were significantly elevated in patients with ESRD. IGFBP-I was also significantly greater in ESRD patients at baseline, as has been previously reported, whereas baseline GHBP was significantly reduced. Previous investigations of patients with chronic renal failure have also observed reduced concentration of GHBP, which may indicate decreased expression of the GH receptor in target tissues, and hence diminished responsiveness to GH in renal failure. The lower concentrations of GHBP may also have contributed to the observed reduction in plasma clearance (and hence increase in AUC) in the ESRD patients compared with healthy subjects. A PK study of intravenous GH administration found a strong positive correlation between baseline GHBP concentration and MCR at physiological GH concentrations. In addition, the reduced GH elimination rate observed in GH-deficient patients in another study was explained by lower levels of GHBP, possibly reflecting a reduced GH receptor density and hence clearance.

In contrast to a study of patients with chronic renal failure undergoing dialysis, baseline IGF-I was not significantly higher in patients compared with healthy controls in the present study. In general, patients with ESRD appear to exhibit normal or high concentrations of IGF-I and considerably elevated concentrations of IGFBP-I and IGFBP-III, which increase with declining renal function, demonstrating that the GH–IGF-I axis is affected on several levels.

There was no marked effect of dialysis on GH PK and PD parameters, assessed in patients only on Days 8–9. The differences observed in AUC and Cmax between steady-state and dialysis were judged to be of no clinical significance.

To date, a number of trials have demonstrated a benefit of GH treatment in patients with ESRD. Major adverse events have not been reported and GH does not appear to accumulate in the circulation of ESRD patients. However, further trials are needed to assess the ultimate effects of GH treatment on morbidity and mortality.

Acknowledgements

This study was supported by Novo Nordisk A/S, 2880 Bagsvaerd, Denmark. The authors would like to thank Ulrike Petry, local trial manager at Novo Nordisk Pharma GmbH, the Clinical staff at APEX Research and also the subjects for their interest in the study. Dr Andreas Möller and Bioprof are acknowledged for performing the efficacy analyses, as are Alois Moritz and Spranger Laboratories for carrying out the safety and screening analyses.

References

1 Pupim, L.B., Cuppari, L. & Ikizler, T.A. (2006) Nutrition and metabolism in kidney disease. Seminars in Nephrology, 26, 134–157.
2 Kalantar-Zadeh, K. (2005) Recent advances in understanding the malnutrition–inflammation–cachexia syndrome in chronic kidney disease patients: What is next? Seminars in Dialysis, 18, 365–369.
3 Burrowes, J.D., Larive, B., Chertow, G.M., Cockram, D.B., Dwyer, J.T., Greene, T., Kusek, J.W., Leung, J. & Rocco, M.V. (2005) Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the hemodialysis (HEMO) study, Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association – European Renal Association, 20, 2765–2774.
4 Pupim, L.B. & Ikizler, T.A. (2003) Uremic malnutrition: new insights into an old problem. Seminars in Dialysis, 16, 224–232.
5 Kalantar-Zadeh, K., Kopple, J.D., Block, G. & Humphreys, M.H. (2001) A malnutrition–inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. American Journal of Kidney Diseases, 38, 1251–1263.
6 Mehrotra, R. & Kopple, J.D. (2001) Nutritional management of maintenance dialysis patients: why aren’t we doing better? Annual Review of Nutrition, 21, 343–379.
7 Ikizler, T.A., Wingard, R.L., Harvell, J., Shyr, Y. & Hakim, R.M. (1999) Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney International, 55, 1945–1951.
8 Ikizler, T.A. & Hakim, R.M. (1996) Nutrition in end-stage renal disease. Kidney International, 50, 343–357.
9 Lowrie, E.G. & Lew, N.L. (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Diseases, 15, 458–482.
10 Bossola, M., Muscaritoli, M., Tzza, L., Giungi, S., Tortorelli, A., Fanelli, F.R. & Luciani, G. (2005) Malnutrition in hemodialysis patients. What therapy? American Journal of Kidney Diseases, 46, 371–386.
11 Kalantar-Zadeh, K., Block, G., McAllister, C.J., Humphreys, M.H. & Kopple, J.D. (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. American Journal of Clinical Nutrition, 80, 299–307.
12 Johannsson, G. & Ahlmen, J. (2003) End-stage renal disease: endocrine aspects of treatment. Growth Hormone and IGF Research, 13 (Suppl. A), S94–S101.
13 Iglesias, P., Diez, J., Fernandez-Reyes, M.J., Aguiler, A., Burgues, S., Martinez-Ara, J., Miguel, J.L., Gomez-Pan, A. & Selgas, R. (1998)
Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. *American Journal of Kidney Diseases, 32*, 454–463.

14 Johansson, G., Bengtsson, B.A. & Ahlmen, J. (1999) Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. *American Journal of Kidney Diseases, 33*, 709–717.

15 Jensen, P.B., Hansen, T.B., Frystyk, J., Ladeloged, S.D., Pedersen, E.B. & Christiansen, J.S. (1999) Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. *Clinical Nephrology, 52*, 103–109.

16 Hansen, T.B., Gram, J., Jensen, P.B., Christiansen, J.H., Ekelund, B., Christiansen, J.S. & Pedersen, E.B. (2000) Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis: a double-blind, randomized, placebo-controlled study. *Clinical Nephrology, 53*, 99–1007.

17 Garibotto, G., Barreca, A., Russo, R., Sofia, A., Araghi, P., Cesarone, A., Malaspina, M., Fiorini, E., Minuto, F. & Tizianello, A. (1997) Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. *Journal of Clinical Investigation, 99*, 97–105.

18 Pupim, L.B., Flakoll, P.J., Yu, C. & Ikizler, T.A. (2005) Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. *American Journal of Clinical Nutrition, 82*, 1235–1243.

19 Sohmiya, M., Ishikawa, K. & Kato, Y. (1998) Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure. *European Journal of Endocrinology/European Federation of Endocrine Societies, 138*, 302–306.

20 Kotzmann, H., Yilmaz, N., Lercher, P., Riedl, M., Schmidt, A., Schuster, E., Kreuzer, S., Geyer, G., Frisch, H., Horl, W.H., Mayer, G. & Lugur, A. (2001) Differential effects of growth hormone therapy in malnourished hemodialysis patients. *Kidney International, 60*, 1578–1585.

21 Feldt-Rasmussen, B., Lange, M., Sulowicz, W., Gaftner, U., Lai, K.N., Wiedemann, J., Christiansen, J.S. & El Nahas, M. (2007) Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. *Journal of American Society of Nephrology, 18*, 2161–2171.

22 Ericsson, E., Filho, J.C. & Lindgren, B.F. (2004) Growth hormone treatment in hemodialysis patients – a randomized, double-blind, placebo-controlled study. *Scandinavian Journal of Urology and Nephrology, 38*, 340–347.

23 Haffner, D., Schaefer, F., Girard, J., Ritz, E. & Mehls, O. (1994) Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. *Journal of Clinical Investigation, 93*, 1163–1171.

24 Schaefer, F., Baumann, G., Haffner, D., Faunt, L.M., Johnson, M.L., Mercado, M., Ritz, E., Mehls, O. & Veldhuis, J.D. (1996) Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. *Journal of Clinical Endocrinology and Metabolism, 81*, 22–31.

25 Garcia-Mayor, R.V., Perez, A.J., Gandara, A., Andrade, A., Mallo, F. & Casasnovas, F.F. (1993) Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. *Clinical Endocrinology, 39*, 337–343.

26 Food and Drug Administration. (1999) *Guidance for Industry: Population Pharmacokinetics*. US Department of Health and Human Services. Available at: http://www.fda.gov/cder/guidance/1852fnl.pdf (accessed 26 June 2007)

27 World Medical Association Declaration of Helsinki. (2000) Ethical principles for medical research involving human subjects. *Journal of the American Medical Association, 284*, 3043–3045.

28 International Conference on Harmonisation. (1996) ICH Harmonised Tripartite Guideline for Good Clinical Practice. Geneva, Switzerland. Available at: http://www.ich.org/LOB/media/MEDIA482.pdf (accessed 26 June 2007)

29 Jacobsen, L.V., Rolan, P., Christensen, M.S., Knudsen, K.M. & Rasmussen, M.H. (2000) Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution: growth hormone and IGF research. *Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 10*, 93–98.

30 de, M., Klinger, I., Kefer, G., King, T. & Harrison, E. (2001) Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems. *Arzneimittelforschung, 51*, 613–617.

31 Agersø, H., Møller-Pedersen, J., Cappi, S., Thomann, P., Jesussek, B. & Senderovitz, T. (2002) Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. *Journal of Clinical Pharmacology, 42*, 1262–1268.

32 Boxenbaum, H. (1998) Pharmacokinetics tricks and traps: flip-flop models. *Journal of Pharmacy and Pharmaceutical Sciences, 1*, 90–91.

33 Catalina, P.F., Andrade, M.A., Garcia-Mayor, R.V. & Mallo, F. (2002) *Growth Hormone Research Society*. (2001) Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. *Journal of Clinical Endocrinology and Metabolism, 86*, 1868–1870.

34 Park, P. & Cohen, P. (2004) The role of insulin-like growth factor I monitoring in growth hormone-treated children. *Hormone Research, 62*, 59–62.

35 Lee, P.D., Hintz, R.L., Sperry, J.B., Baxter, R.C. & Powell, D.R. (1989) IGF binding proteins in growth-retarded children with chronic renal failure. *Pediatrics Research, 26*, 308–315.

36 Blum, W.F., Ranke, M.B., Kietzmann, K., Tonshoff, B. & Mehls, O. (1991) Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. *Pediatrics Nephrology, 5*, 539–544.

37 Maheshwari, H.G., Rifkin, I., Butler, J. & Norman, M. (1992) Growth hormone resistance and inhibition of somatomedin C in diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism, 78*, 1469–1473.

38 Catalina, P.F., Paramo, C., Andrade, M.A. & Mallo, F. (2007) Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency. *Clinical Endocrinology, 66*, 341–347.